NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, Price Target & More

Question 1

What is Arena Pharmaceuticals' stock symbol?

Answer

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Question 2

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Answer

Arena Pharmaceuticals's stock reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Question 3

How were Arena Pharmaceuticals' earnings last quarter?

Answer

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its quarterly earnings results on Wednesday, March, 14th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.30. The biopharmaceutical company earned $15.40 million during the quarter, compared to analyst estimates of $5.75 million. Arena Pharmaceuticals had a negative return on equity of 62.82% and a negative net margin of 250.93%. Arena Pharmaceuticals's revenue was down 77.8% on a year-over-year basis. During the same quarter last year, the business posted $1.60 earnings per share. View Arena Pharmaceuticals' Earnings History.

Question 4

When is Arena Pharmaceuticals' next earnings date?

Answer

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Arena Pharmaceuticals.

Question 5

What price target have analysts set for ARNA?

Answer

7 analysts have issued 12 month price objectives for Arena Pharmaceuticals' stock. Their predictions range from $44.00 to $79.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $58.00 in the next twelve months. View Analyst Ratings for Arena Pharmaceuticals.

Question 6

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Answer

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:

1. Needham & Company LLC analysts commented, "Arena mgmt provided a corporate update today in a 4Q17 conference call. Mgmt reiterated guidance for top-line results from etrasimod Phase 2 trial in Ulcerative Colitis (UC) later this month. Preclinical and Phase 1 data suggest the drug has the potential for differentiation in the S1P receptor modulator space. We await outcome, maintaining HOLD. Mgmt also discussed ralinepag Phase 3 trial design in Pulmonary Arterial Hypertension (PAH). Three trials are planned, two of which mgmt believes are independently sufficient for regulatory approval. Mgmt plans to provide more details around cost and time to completion mid-2018 after protocols are finalized." (3/14/2018)
2. According to Zacks Investment Research, "Arena’s only approved product is Belviq, used for chronic weight management. Though it was the first obesity drug to be approved by the FDA in over a decade, is yet to impress with its performance. However, the company’s partnership agreements and efforts to improve the performance of the drug are impressive. We are also encouraged by the company’s cost-reduction initiatives to streamline the organization to support its development programs. Shares of the company have outperformed the industry in the last one year. On the flip side, Arena’s pipeline consists of early-to-mid stage candidates, still several years from commercialization. Plus, competition remains intense in the obesity market with both branded and generic players. " (3/9/2018)
3. Cantor Fitzgerald analysts commented, "KOL event could fill in some important blank spaces. ARNA will host a lunch event on January 29 (12:30-1:30 pm) in NYC with two physician consultants to discuss modulators of S1P receptors and etrasimod, specifically. We believe the event could be helpful for investors as it relates to understanding important pharmacokinetic and pharmacodynamic properties of the drug candidate that we highlighted in a recent research report (here)." (1/17/2018)

Question 7

Are investors shorting Arena Pharmaceuticals?

Answer

Arena Pharmaceuticals saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 3,192,659 shares, an increase of 71.8% from the March 15th total of 1,858,178 shares. Based on an average trading volume of 4,246,081 shares, the short-interest ratio is presently 0.8 days. Approximately 6.7% of the company's shares are sold short.

Question 8

Who are some of Arena Pharmaceuticals' key competitors?

Answer

Some companies that are related to Arena Pharmaceuticals include Alkermes (ALKS), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).

Question 9

Who are Arena Pharmaceuticals' key executives?

Answer

Arena Pharmaceuticals' management team includes the folowing people:

Tina Susan Nova Ph.D., Independent Chairman of the Board (Age 63)
Amit D. Munshi, President, Chief Executive Officer, Director (Age 49)
Kevin R. Lind, Chief Financial Officer, Executive Vice President (Age 41)
Steven W. Spector J.D., Executive Vice President, General Counsel, Secretary (Age 52)
Vincent Aurentz, Executive Vice President and Chief Business Officer (Age 49)
Preston S. Klassen M.D., Executive Vice President - Research & Development, Chief Medical Officer (Age 48)
Jennifer Jarrett, Director (Age 46)
Scott H. Bice J.D., Independent Director (Age 74)
Jayson Dallas M.D., Independent Director (Age 49)
Oliver S. Fetzer Ph.D., Independent Director (Age 52)

Question 10

Has Arena Pharmaceuticals been receiving favorable news coverage?

Answer

News headlines about ARNA stock have trended positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arena Pharmaceuticals earned a daily sentiment score of 0.35 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 48.19 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Question 11

Who are Arena Pharmaceuticals' major shareholders?

Answer

Arena Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (10.92%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christine Anna White and Steven W Spector. View Institutional Ownership Trends for Arena Pharmaceuticals.

Question 12

How do I buy shares of Arena Pharmaceuticals?

Answer

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 13

What is Arena Pharmaceuticals' stock price today?

Answer

One share of ARNA stock can currently be purchased for approximately $40.01.

Question 14

How big of a company is Arena Pharmaceuticals?

Answer

Arena Pharmaceuticals has a market capitalization of $1.90 billion and generates $21.34 million in revenue each year. The biopharmaceutical company earns $-91,400,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Arena Pharmaceuticals employs 159 workers across the globe.

Question 15

How can I contact Arena Pharmaceuticals?

Answer

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		232 (Vote Outperform)
Underperform Votes:		259 (Vote Underperform)
Total Votes:		491

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	2.88	2.71
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$58.00	$58.00	$41.1429	$38.8333
Price Target Upside:	44.96% upside	45.91% upside	21.44% upside	54.78% upside

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/21/2018	Citigroup	Reiterated Rating	Positive -> Buy	$62.00	High
3/20/2018	JMP Securities	Boost Price Target	Mkt Outperform -> Outperform	$63.00 -> $79.00	High
3/20/2018	Wells Fargo	Lower Price Target	Positive -> Outperform	$53.00 -> $60.00	High
3/20/2018	Needham & Company LLC	Upgrade	Hold -> Buy	$30.89 -> $60.00	High
1/17/2018	Credit Suisse Group	Initiated Coverage	Outperform -> Outperform	$44.00	Low
1/17/2018	Leerink Swann	Reiterated Rating	Outperform -> Positive	$53.00 -> $56.00	Low
1/17/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$45.00	Low
3/16/2017	FBR & Co	Reiterated Rating	Outperform	$60.00	Medium
8/10/2016	Jefferies Group	Reiterated Rating	Buy		N/A
8/8/2016	JPMorgan Chase	Reiterated Rating	Hold		N/A

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.78)	($0.78)	($0.78)
Q2 2018	1	($0.80)	($0.80)	($0.80)
Q3 2018	1	($0.83)	($0.83)	($0.83)
Q4 2018	1	($0.87)	($0.87)	($0.87)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.68)					N/A
3/14/2018	Q4 2017	($0.65)	($0.35)	$5.75 million	$15.40 million	View	Listen
11/7/2017	Q3 2017	($0.66)	($0.65)	$5.48 million	$7.95 million	View	N/A
8/7/2017	Q2 2017	($0.74)	($0.77)	$5.58 million	$6.49 million	View	N/A
5/9/2017	Q1 2017	($0.82)	($0.90)	$4.84 million	$6.60 million	View	N/A
3/14/2017	Q4 2016	($0.80)	$1.60	$14.12 million	$85.40 million	View	N/A
11/7/2016	Q316	($0.70)	($0.50)	$13.99 million	$19.20 million	View	N/A
8/8/2016	Q216	($1.00)	($1.10)	$10.44 million	$9.50 million	View	N/A
5/9/2016	Q116	($1.00)	($0.90)	$9.02 million	$9.80 million	View	N/A
2/29/2016	Q415	($1.30)	($1.30)	$8.26 million	$7.80 million	View	N/A
11/10/2015	Q315	($1.30)	($1.10)	$8.87 million	$9.10 million	View	N/A
8/5/2015	Q215	($1.40)	($1.10)	$10.95 million	$9.18 million	View	N/A
5/11/2015	Q115	($1.40)	($1.00)	$10.56 million	$12.30 million	View	N/A
3/2/2015	Q414	($1.20)	($1.50)	$10.36 million	$9.20 million	View	N/A
11/3/2014	Q314	($1.30)	($0.50)	$10.90 million	$8.20 million	View	N/A
8/1/2014	Q2 14	($1.10)	($1.20)	$9.81 million	$12.80 million	View	N/A
5/12/2014	Q114	($1.00)	($1.20)	$7.98 million	$6.80 million	View	N/A
2/27/2014	Q413	$0.20	($1.10)	$7.00 million	$6.50 million	View	N/A
11/7/2013	Q313	($1.20)	($0.80)	$5.30 million	$3.60 million	View	N/A
8/1/2013	Q2 2013	$1.50	$1.80	$57.30 million	$68.90 million	View	N/A
4/30/2013	Q1 2013	$1.10	$0.90	$50.36 million	$2.37 million	View	N/A
3/4/2013	Q4 2012	($0.30)	($1.00)	$21.94 million	$1.94 million	View	N/A
11/6/2012	Q312	($1.10)	($0.70)	$3.72 million	$1.50 million	View	N/A
8/9/2012		($0.80)	($1.20)			View	N/A
5/1/2012	Q1 2012	($1.30)	($1.54)			View	N/A
3/14/2012	Q4 2011	($1.50)	($1.62)			View	N/A
11/9/2011		($1.40)	($1.60)			View	N/A
8/9/2011		($1.50)	($1.60)			View	N/A
5/10/2011		($2.10)	($3.50)			View	N/A
3/11/2011		($2.20)	($2.30)			View	N/A
11/9/2010	Q3 2010	($2.30)	($3.09)			View	N/A
8/3/2010	Q2 2010	($2.80)	($2.76)			View	N/A
5/7/2010	Q1 2010	($3.20)	($3.30)			View	N/A
3/12/2010	Q4 2009	($3.00)	($3.76)			View	N/A
11/9/2009	Q3 2009	($3.40)	($3.83)			View	N/A
8/3/2009	Q2 2009	($4.80)	($4.80)			View	N/A
5/11/2009	Q1 2009	($6.90)	($6.82)			View	N/A
3/12/2009	Q4 2008	($7.80)	($8.44)			View	N/A
10/30/2008	Q3 2008	($8.30)	($7.60)			View	N/A
8/5/2008	Q2 2008	($7.30)	($8.92)			View	N/A
5/7/2008	Q1 2008	($6.70)	($7.47)			View	N/A
2/27/2008	Q4 2007	($8.20)	($5.98)			View	N/A

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/16/2018	Steven W Spector	EVP	Sell	30,001	$34.57	$1,037,134.57	34,691
5/12/2017	Amit Munshi	Insider	Buy	25,000	$1.19	$29,750.00	76,875
4/26/2017	Amit Munshi	Insider	Buy	50,000	$1.41	$70,500.00	1,875
6/13/2016	Christine Anna White	Director	Sell	18,728	$1.99	$37,268.72	85,529
3/30/2015	Randall E Woods	Director	Sell	76,268	$4.49	$342,443.32
3/17/2015	Steven W Spector	EVP	Sell	70,000	$5.00	$350,000.00
1/8/2015	Steven W Spector	EVP	Sell	45,000	$6.26	$281,700.00
1/7/2015	William R Shanahan Jr	SVP	Sell	50,000	$5.49	$274,500.00
7/1/2014	Jack Lief	CEO	Sell	223,525	$5.85	$1,307,621.25
6/27/2014	Donald D Belcher	Director	Sell	2,473	$5.85	$14,467.05
5/6/2014	Donald Belcher	Director	Sell	4,176	$7.00	$29,232.00	68,728
4/22/2014	Harry Hixson, Jr.	Director	Sell	36,900	$6.31	$232,839.00	82,876
4/14/2014	Tina Susan Nova	Director	Sell	35,000	$6.22	$217,700.00	18,728
4/1/2014	Donald Belcher	Director	Sell	1,905	$6.45	$12,287.25	68,728
4/1/2014	William Shanahan, Jr.	SVP	Sell	60,000	$6.37	$382,200.00	35,000
3/4/2014	Steven Spector	EVP	Sell	25,000	$7.01	$175,250.00	101,794
1/17/2014	Jack Lief	CEO	Sell	100,000	$7.81	$781,000.00	583,704
1/10/2014	Dominic Behan	EVP	Sell	33,332	$6.25	$208,325.00	483,000
9/10/2013	Dominic P Behan	EVP	Sell	200,000	$6.31	$1,262,000.00
9/5/2013	Steven W Spector	EVP	Sell	20,000	$6.54	$130,800.00
5/21/2013	Craig Michael Audet	SVP	Sell	83,750	$8.00	$670,000.00

Date	Headline
	$1.01 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter www.americanbankingnews.com - April 21 at 4:40 AM
	Arena Pharmaceuticals (ARNA) Receives New Coverage from Analysts at Citigroup www.americanbankingnews.com - April 20 at 3:01 PM
	Arena Pharmaceuticals (ARNA) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - April 20 at 11:55 AM
	Arena Pharmaceuticals (ARNA) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - April 20 at 7:46 AM
	Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials seekingalpha.com - April 19 at 4:13 PM
	Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Announce -$0.70 EPS www.americanbankingnews.com - April 19 at 9:07 AM
	Arena Pharmaceuticals, Inc. (ARNA) EVP Sells $1,037,134.57 in Stock www.americanbankingnews.com - April 18 at 7:13 PM
	Arena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - April 18 at 9:07 AM
	Arena CEO: We have two great assets and are trying to bui... finance.yahoo.com - April 17 at 4:13 PM
	Arena Pharmaceuticals (ARNA) Stock Rating Lowered by ValuEngine www.americanbankingnews.com - April 17 at 11:05 AM
	Arena Pharmaceuticals (ARNA) Rating Lowered to Sell at BidaskClub www.americanbankingnews.com - April 16 at 9:16 PM
	Arena Pharmaceuticals, Inc. (ARNA) Sees Significant Increase in Short Interest www.americanbankingnews.com - April 14 at 1:40 AM
	Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue? finance.yahoo.com - April 13 at 4:08 PM
	Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting finance.yahoo.com - April 12 at 10:54 AM
	This $3 Medical Device Stock be Worth $9-14 with Impending Product Launch finance.yahoo.com - April 5 at 8:24 AM
	Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Announce Quarterly Sales of $1.01 Million www.americanbankingnews.com - April 4 at 4:18 AM
	Arena Pharmaceuticals, Inc. (ARNA) Expected to Post Earnings of -$0.70 Per Share www.americanbankingnews.com - April 2 at 7:22 AM
	Arena Pharmaceuticals (ARNA) Upgraded to "Outperform" by Wells Fargo www.americanbankingnews.com - March 31 at 12:12 AM
	Arena Pharmaceuticals Inc (NASDAQ:ARNA): Earnings Growth Remains Elusive finance.yahoo.com - March 29 at 4:01 PM
	Arena Pharmaceuticals (ARNA) Stock Rating Lowered by Zacks Investment Research www.americanbankingnews.com - March 29 at 12:45 PM
	BidaskClub Lowers Arena Pharmaceuticals (ARNA) to Buy www.americanbankingnews.com - March 28 at 11:56 AM
	Arena Pharmaceuticals (ARNA) Earns "Buy" Rating from Cantor Fitzgerald www.americanbankingnews.com - March 27 at 10:23 PM
	Arena Pharmaceuticals' (ARNA) "Positive" Rating Reaffirmed at Leerink Swann www.americanbankingnews.com - March 27 at 6:16 PM
	Arena Pharmaceuticals Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares finance.yahoo.com - March 27 at 10:12 AM
	Arena Pharmaceuticals (ARNA) Upgraded at BidaskClub www.americanbankingnews.com - March 26 at 8:58 AM
	Arena Pharmaceuticals (ARNA) Cut to Buy at BidaskClub www.americanbankingnews.com - March 25 at 12:50 AM
	Citigroup Boosts Arena Pharmaceuticals (ARNA) Price Target to $55.00 www.americanbankingnews.com - March 24 at 9:28 PM
	3 Biotech Stocks That Skyrocketed This Week: Are They Buys? finance.yahoo.com - March 24 at 4:28 PM
	Arena Pharmaceuticals (ARNA) Downgraded by BidaskClub to Sell www.americanbankingnews.com - March 24 at 1:54 PM
	Arena Pharmaceuticals, Inc. (ARNA) Given Average Recommendation of "Buy" by Analysts www.americanbankingnews.com - March 24 at 8:29 AM
	Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27 - PR Newswire (press release) www.prnewswire.com - March 24 at 8:10 AM
	Arena Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference on March 27 finance.yahoo.com - March 24 at 8:09 AM
	Arena Pharmaceuticals (ARNA) Rating Increased to Hold at ValuEngine www.americanbankingnews.com - March 23 at 11:22 PM
	Arena Pharmaceuticals Takes Aim at Celgene finance.yahoo.com - March 23 at 6:24 PM
	One Biotech Turnaround to Watch finance.yahoo.com - March 23 at 9:37 AM
	Arena Raises Impressive $352 Million On Stock Offering - Seeking Alpha seekingalpha.com - March 22 at 4:13 PM
	Arena Pharmaceuticals (ARNA) in Focus: Stock Moves 10.7% Higher finance.yahoo.com - March 22 at 9:52 AM
	Leerink Swann Weighs in on Arena Pharmaceuticals, Inc.'s Q2 2018 Earnings (ARNA) www.americanbankingnews.com - March 22 at 9:34 AM
	Traders Purchase High Volume of Arena Pharmaceuticals Put Options (ARNA) www.americanbankingnews.com - March 22 at 7:16 AM
	Here's Why Arena Pharmaceuticals, Inc. Surged Again on Wednesday finance.yahoo.com - March 21 at 4:14 PM
	Arena Pharmaceuticals' (ARNA) "Buy" Rating Reaffirmed at Citigroup www.americanbankingnews.com - March 21 at 1:56 PM
	Here's Why Arena Pharmaceuticals Jumped 30% Today www.msn.com - March 21 at 10:50 AM
	Arena Pharma (ARNA) to Offer 7.5M Shares of Common Stock www.streetinsider.com - March 21 at 10:50 AM
	Arena Pharmaceuticals shares tick lower on secondary offering www.marketwatch.com - March 21 at 10:50 AM
	Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal finance.yahoo.com - March 21 at 10:50 AM
	Today’s Research Reports on Trending Tickers: Arena Pharmaceuticals and CASI Pharmaceuticals finance.yahoo.com - March 21 at 10:50 AM
	Arena's (ARNA) Etrasimod Meets Phase II Colitis Study Goal - Nasdaq www.nasdaq.com - March 20 at 4:12 PM
	ARNA Soars After-hours, Remoxy Now 2 Steps Away From Approval, APLS On Watch - Nasdaq www.nasdaq.com - March 20 at 4:12 PM
	Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock - PR Newswire (press release) www.prnewswire.com - March 20 at 4:12 PM
	Arena Pharma (ARNA) to Offer 7.5M Shares of Common Stock - StreetInsider.com www.streetinsider.com - March 20 at 4:12 PM

NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, Price Target & More

About Arena Pharmaceuticals (NASDAQ:ARNA)

Receive ARNA News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

How were Arena Pharmaceuticals' earnings last quarter?

When is Arena Pharmaceuticals' next earnings date?

What price target have analysts set for ARNA?

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Are investors shorting Arena Pharmaceuticals?

Who are some of Arena Pharmaceuticals' key competitors?

Who are Arena Pharmaceuticals' key executives?

Has Arena Pharmaceuticals been receiving favorable news coverage?

Who are Arena Pharmaceuticals' major shareholders?

How do I buy shares of Arena Pharmaceuticals?

What is Arena Pharmaceuticals' stock price today?

How big of a company is Arena Pharmaceuticals?

How can I contact Arena Pharmaceuticals?

MarketBeat Community Rating for Arena Pharmaceuticals (ARNA)

Analyst Ratings

Arena Pharmaceuticals (NASDAQ:ARNA) Price Target and Consensus Rating

Arena Pharmaceuticals (NASDAQ:ARNA) Consensus Price Target History

Arena Pharmaceuticals (NASDAQ:ARNA) Analyst Ratings History

Earnings

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings History and Estimates Chart

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings Estimates

Arena Pharmaceuticals (NASDAQ ARNA) Earnings History by Quarter

Dividends

Arena Pharmaceuticals (NASDAQ:ARNA) Dividend History by Quarter

Insider Trades

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading and Institutional Ownership History

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading History

Headlines

Arena Pharmaceuticals (NASDAQ ARNA) News Headlines

SEC Filings

Arena Pharmaceuticals (NASDAQ:ARNA) SEC Filings

Social Media

Financials

Arena Pharmaceuticals (NASDAQ:ARNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arena Pharmaceuticals (NASDAQ ARNA) Stock Chart for Wednesday, April, 25, 2018